GE HealthCare, renowned for its innovations in medical technology, pharmaceutical diagnostics, and digital solutions, has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for approval of CleaRecon DL. This cutting-edge deep learning technology aims to uplift the quality of cone-beam computed tomography (CBCT) imaging by integrating AI-powered 3D reconstruction within the interventional suite. This advanced tool was showcased at the 2024 Annual Meeting of the Radiological Society of North America (RSNA), held in Chicago from December 1-4.
As the trend towards minimally invasive procedures continues to rise, GE HealthCare remains devoted to eliminating obstacles in image guidance technologies to aid clinicians in maximizing their potential. The ultimate objective is to enhance both clinical and operational outcomes for healthcare providers.
CleaRecon DL, intended for integration with Allia Image-Guided Solutions (IGS) Systems, employs AI-driven reconstruction to enhance image clarity by eliminating streaks while preventing any unwanted artifacts. This innovation is aimed at refining CBCT analysis through clearer imagery, thereby supporting the wider adoption of CBCT in everyday medical practice.
“GE HealthCare has led the CBCT revolution for over twenty years, perpetually innovating with solutions like augmented guidance that improve procedural results, and wide-bore platforms that accommodate CBCT imaging even in obese patients,” stated Arnaud Marie, Global Interventional General Manager at GE HealthCare. “For years, issues like scan artifacts from natural body movements and contrast distribution have complicated the use of CBCT, hindering its integration. CleaRecon DL was specifically designed to address this, thereby facilitating advanced imaging benefits for physicians and patients.”
Beyond CleaRecon DL, GE HealthCare is also debuting OnWatch Predict. This predictive tool monitors interventional image-guided systems to ensure reliable service and heightened system readiness for timely diagnosis and treatments. By synchronizing ongoing system checks with user interface evaluations, image chain assessments, and X-ray outputs, OnWatch Predict anticipates potential component failures, allowing preemptive maintenance scheduling to minimize unexpected downtimes.
Stand as a global frontrunner in medical technology, GE HealthCare remains steadfast in delivering comprehensive solutions and services, alongside data analytics, to render hospitals more efficient, clinicians more competent, therapies more accurate and patients healthier and more content.